 | ||||||||||||
|
| Research and Markets: Gram-Positive Bacterial Infections - Pipeline Review, H1 ... Global Markets Direct's, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial ... Fort Mills Times - Wed, 01 May 2013 05:32 | |
| Recently released market study: Gram-Positive Bacterial Infections - Pipeline ... [USPRwire, Mon May 13 2013] Global Markets Direct's, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for ... USPRwire (press release) - Mon, 13 May 2013 16:12 | |
| Gram-Positive Bacterial Infections & Cutaneous T-Cell Lymphoma - Pipeline ... Global Markets Directs, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial ... DigitalJournal.com (press release) - Sat, 20 Apr 2013 05:37 | |
| Gram-Positive Bacterial Infections - Pipeline Review, H1 2013 Research Report ... It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs ... SBWire (press release) - Mon, 22 Apr 2013 07:28 | |
| Basilea reports presentation of new data on anti-infective drug candidates ... Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that new data on drug candidates from its development pipeline were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held in Berlin, Germany, from April ... Stockhouse - Sun, 28 Apr 2013 23:19 | |
| Trius Therapeutics: New, Positive Dimension For Investment Outlook ... the emergence of bacteria resistant to daptomycin. Daptomycin plays a major role in treating bacteremia (systemic infections including those of the blood and heart) and the emergence of resistance is a serious clinical concern. This discovery led ... Seeking Alpha - Mon, 13 May 2013 15:27 | |
| Trius Announces Notice of Allowance of US Patent Application Related to ... Wall Street Journal (press release) - Mon, 13 May 2013 05:09 | |
| Durata Announces Data from Phase I Trial of Dalbavancin Durata Therapeutics, Inc. (Nasdaq: DRTX) today announced data from a Phase 1 study of its lead product candidate, dalbavancin, under investigation for the treatment of susceptible gram positive bacterial infections including MRSA. The data, presented ... Benzinga - Mon, 29 Apr 2013 04:38 | |
| New Data Demonstrating In Vitro Potency of Dalbavancin Against Bacterial ... Wall Street Journal (press release) - Mon, 29 Apr 2013 04:37 | |
| Is MRSA the Godzilla of Superbugs? Penicillin, though, differs from carbapenems in that it typically treats Gram-positive bacteria (like Staph A) rather than Gram-negative bacteria. After Staph ... What happens—is there anything doctors can use to fight this powerful bacterial ... Yahoo! News - Fri, 17 May 2013 16:20 |